Boston, December 17, 2018 – Pear Therapeutics, Inc. today announced the initiation of a Phase 2, proof of concept study for its prescription digital therapeutic in development for schizophrenia. The treatment, known as Pear-004, is designed to deliver multimodal neurobehavioral interventions to improve symptoms and functioning of people with schizophrenia. Pear-004 includes social skills training, cognitive behavioral therapy for psychosis, and illness self-management training aimed at delivering efficacy in combination with standard of care anti-psychotic medication. The treatment is being developed in collaboration with Novartis, as part of an agreement announced in March2018.
1 Like
I saw this on clinicaltrials.gov. It sounds like a smartphone type app. Maybe a little more complex, but… they also have one for substance abuse